CNP-106 is under clinical development by Cour Pharmaceuticals Development and currently in Phase II for Myasthenia Gravis. According to GlobalData, Phase II drugs for Myasthenia Gravis have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CNP-106’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CNP-106 overview
CNP-106 is under development for the treatment of generalized myasthenia gravis. The therapeutic candidate comprises a polymeric shell encapsulating purified protein, an antigenic AChR peptide pool. It is developed based on COUR nanoparticle platform (CNP). It is administered through intravenous route.
Cour Pharmaceuticals Development overview
Cour Pharmaceuticals Development (Cour) is a clinical-stage biotechnology company that develops novel medicines to treat immune diseases by applying nonbiological technology. Its pipeline products include CNP-101 and TAK-101 to treat celiac disease; CNP-201 to treat peanut allergy; CNP-104 to treat primary biliary cholangitis; CNP-T1D to treat type 1 diabetes; CNP-107 treat vitiligo; CNP-106 myasthenia gravis and CNP-108 to treat T-cell immunogenicity in gene and protein therapies. It uses immune modifying nanoparticles (IMP) and tolerating immune modifying nanoparticles (TIMP) technologies in developing its pipeline products. Cour is headquartered in Northbrook, Illinois, the US.
For a complete picture of CNP-106’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
